A tough puzzle: complexity slows drug development for concussions

Oct 10

Written By Lindsey McClelland

Condition heterogeneity warrants multiple therapeutic approaches, but past failures highlight developmental challenges.

Adam ZamecnikSeptember 12, 2022

Lindsey McClelland

The injection of Ghrelin (OXE-103) improves subacute concussion symptom burden and quality of life

Roll Call: We need more than brain injury awareness: We need new treatment